Healthcare entity
The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. TD Cowen is most often covered alongside Amylyx Pharmaceuticals, which appears in 1 of these 3 stories. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: 5d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is market-trends: 2 of 3 stories, with the rest divided among 1 other category. TD Cowen is most often covered alongside Amylyx Pharmaceuticals, which appears in 1 of these 3 stories. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. Across a 164-day span, the pace is roughly 0.1 stories per week. Their average consequence score of 5.7 runs below the beat's 6 for that window. This profile follows 3 Healthcare stories mentioning TD Cowen across the period from March 8, 2026 to August 18, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 921 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TD Cowen. Shared-story counts are live from our verified record — not editorial picks.
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
A late-stage trial found Amylyx's once-daily injection avexitide reduced hypoglycemic episodes by 55% in people with post-bariatric hypoglycemia, a condition with no approved treatments. The drug was well tolerated, and the company plans a U.S. filing by end of 2026. For health systems and clinicians, the result signals a potential first-ever standard therapy that could change post-bariatric care.
Source: arynews.tv · medscape.com
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Source: finance.yahoo.com · fool.com
Veeva Systems is facing a wave of price target reductions from major analysts, including TD Cowen and Canaccord Genuity, reflecting caution over its platform transition. While management maintains a $6 billion revenue target for 2030, recent disclosures of competitive losses have tempered market enthusiasm.
Source: defenseworld.net · defenseworld.net
TD Cowen is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
